Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956507 | 1.00 | RAD51 (0.42) | RAD51CA1CA2KIF11GABRP | |
| SCHEMBL31124554 | 0.89 | FFAR1 (0.36) | RAD51KIF11P4HBERN1 | |
| SCHEMBL29956520 | 0.84 | RAD51 (0.39) | RAD51CA1CA2KIF11HSD17B14 | |
| SCHEMBL921358 | 0.84 | RAD51 (0.39) | RAD51CA1CA2KIF11HSD17B14 | |
| SCHEMBL29642158 | 0.81 | RAD51 (0.40) | RAD51CA1CA2KIF11HSD17B14 | |
| SCHEMBL23835197 | 0.80 | RAD51 (0.39) | RAD51KIF11PIN1MEN1KMT2A | |
| SCHEMBL1165506 | 0.80 | ERN1 (0.34) | CA1CA2MEN1KMT2AERN1 | |
| SCHEMBL31159880 | 0.80 | RAD51 (0.39) | RAD51KIF11PIN1MEN1KMT2A | |
| SCHEMBL4680994 | 0.79 | RAD51 (0.40) | RAD51CA1CA2PIN1MEN1 | |
| SCHEMBL4680996 | 0.79 | RAD51 (0.40) | RAD51CA1CA2PIN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107227-A1 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4706757-A2 | 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| EP-4209490-B1 | 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20260015348-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4660194-A1 | SALT AND CRYSTAL FORM OF CYCLOALKENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2025-12-10 | — | — | EP | disclosed |
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | HANMI PHARM. CO., LTD. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-12473279-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-20250346599-A1 | TRICYCLIC PHTHALAZINONE PARP INHIBITORS AND METHODS OF USE | VALO HEALTH INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-5863947-A | Phenylglycine derivatives useful for treating disorders of the central nervous system | ELI LILLY AND COMPANY LIMITED (GB) | 1999-01-26 | — | — | US | disclosed |
| CN-1202893-A | Novel isoxazoline and isoxazole fibrinogen receptor antagonists | DU PONT MERCK PHARMA (US) | 1998-12-23 | — | — | CN | disclosed |
| US-5849736-A | Isoxazoline and isoxazole fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1998016526-A1 | TETRAHYDRO-6H-PYRAZINO[1,2-B]ISOQUINOLINE 1,4-DIONES AS APOPROTEIN B-100 INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-04-23 | — | — | WO | disclosed |
| EP-0832076-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0807621-A1 | Derivatives of phenylglycine and use thereof as pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996038426-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| EP-0730590-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |
| US-4784471-A | LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015348-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | RAD51 3403/4885CA1 1470/4885CA2 602/4885 |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | RAD51 4812/4885CA1 3447/4885CA2 3222/4885 |
| US-12473279-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | GLP1R, GIPR, VIP | RAD51 4461/4885CA1 4676/4885CA2 4204/4885 |
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | KDM1A, KDM1B, KDM2A | RAD51 4338/4885CA1 3423/4885CA2 1873/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | RAD51 4560/4885CA1 4519/4885CA2 2281/4885 |
| US-20250346599-A1 | TRICYCLIC PHTHALAZINONE PARP INHIBITORS AND METHODS OF USE | PARP1, PARP2, PARP3 | RAD51 102/4885CA1 2883/4885CA2 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.